- Ramos Llorens, Marc
- Bello Madruga, Roberto
- Valle, Javier
- Andreu Martínez, David
- Torrent Burgas, Marc
The alarming rise of antibiotic-resistant bacterial infections is driving efforts to develop alternatives to conventional antibiotics. In this context, antimicrobial peptides (AMPs) have emerged as promising candidates for their ability to target a broad range of microorganisms. However, the development of AMPs with optimal potency, selectivity, and/or stability profiles remains a challenge. To address it, computational tools for predicting AMP properties and designing novel peptides have gained increasing attention. PyAMPA is a novel platform for AMP discovery. It consists of five modules, namely AMPScreen, AMPValidate, AMPSolve, AMPMutate, and AMPOptimize, that allow high-throughput proteome inspection, candidate screening, and optimization through point-mutation and genetic algorithms. The platform also offers additional tools for predicting and evaluating AMP properties, including antimicrobial and cytotoxic activity, and peptide half-life. By providing innovative and accessible inroads into AMP motifs in proteomes, PyAMPA will enable advances in AMP development and potential translation into clinically useful molecules. PyAMPA is available at: https://github.com/SysBioUAB/PyAMPA. Importance: This paper introduces PyAMPA, a new bioinformatics platform designed for the discovery and optimization of antimicrobial peptides (AMPs). It addresses the urgent need for new antimicrobials due to the rise of antibiotic-resistant infections. PyAMPA, with its five predictive modules -AMPScreen, AMPValidate, AMPSolve, AMPMutate and AMPOptimize, enables high-throughput screening of proteomes to identify potential AMP motifs and optimize them for clinical use. Its unique approach, combining prediction, design, and optimization tools, makes PyAMPA a robust solution for developing new AMP-based therapies, offering a significant advance in combatting antibiotic resistance., Grants from MCIN, Spanish Ministry of Science and Innovation (PID2020-113184RB-C22/AEI/10.13039/501100011033 to D.A. and PID2020-114627RB-I00/AEI/10.13039/501100011033 to M.T. were funded by MCIN/AEI; PDC2021-121544-I00/AEI/10.13039/501100011033 to M.T. was funded by MCIN/AEI and European Union Next GenerationEU/ PRTR). Work at UPF was also supported by La Caixa Health Foundation (grant HR17-00409 to D.A.) and by MCIN “María de Maeztu” Program for Units of Excellence in R&D (CEX2018-000792-M) to the UPF Department of Medicine and Life Sciences at (MELIS-UPF). Work at UAB was further supported by a 2022 grant from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). R.B.M. is recipient of a pre-doctoral FPI scholarship (PRE2021-097678) from the Spanish Ministerio de Ciencia e Innovación.